Bispecific Antibodies for Non-Hodgkin's Lymphomas and Multiple Myeloma

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2021 Oct 4

PMID 34603459

Citations 5

Authors

Omar Castaneda-Puglianini

Julio C Chavez

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Early-phase studies have shown encouraging clinical activity in poor-risk B cell NHL and MM. Several constructs are currently available and in clinical development for the treatment of these malignancies. Here, we present a narrative review of the most current data on bispecific antibodies in B cell NHL and MM.

Citing Articles

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma.

Avenoso D, Alabdulwahab A, Kenyon M, Mehra V, Krishnamurthy P, Dazzi F Mediterr J Hematol Infect Dis. 2023; 15(1):e2023041.

PMID: 37435036 PMC: 10332350. DOI: 10.4084/MJHID.2023.041.

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.

Huang P, Kan H, Hsu C, Hsieh H, Cheng W, Huang R J Transl Med. 2023; 21(1):346.

PMID: 37226226 PMC: 10210478. DOI: 10.1186/s12967-023-04193-5.

CRISPR screening identifies T cell-intrinsic regulators of CD3-bispecific antibody responses.

Molony R, Funk T, Trabucco G, Corcoran E, Ruddy D, Varadarajan M Front Immunol. 2022; 13:909979.

PMID: 35990699 PMC: 9388929. DOI: 10.3389/fimmu.2022.909979.

The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients.

Derebas J, Panuciak K, Margas M, Zawitkowska J, Lejman M Cancers (Basel). 2022; 14(6).

PMID: 35326719 PMC: 8945992. DOI: 10.3390/cancers14061569.

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.

Swamydas M, Murphy E, Ignatz-Hoover J, Malek E, Driscoll J J Hematol Oncol. 2022; 15(1):17.

PMID: 35172851 PMC: 8848665. DOI: 10.1186/s13045-022-01234-2.

References

Sun L, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y . Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7(287):287ra70. DOI: 10.1126/scitranslmed.aaa4802. View

Patriarca A, Gaidano G . Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2020; 30(1):25-38. DOI: 10.1080/13543784.2021.1855140. View

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

Topp M, Duell J, Zugmaier G, Attal M, Moreau P, Langer C . Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020; 38(8):775-783. DOI: 10.1200/JCO.19.02657. View

Chavez J, Bachmeier C, Kharfan-Dabaja M . CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019; 10:2040620719841581. PMC: 6466472. DOI: 10.1177/2040620719841581. View

Viardot A, Goebeler M, Hess G, Neumann S, Pfreundschuh M, Adrian N . Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016; 127(11):1410-6. PMC: 4797019. DOI: 10.1182/blood-2015-06-651380. View

Smith E, Olson K, Haber L, Varghese B, Duramad P, Tustian A . A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015; 5:17943. PMC: 4675964. DOI: 10.1038/srep17943. View

Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati A . Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988. DOI: 10.1016/S1470-2045(20)30225-4. View

Velasquez M, Bonifant C, Gottschalk S . Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2017; 131(1):30-38. PMC: 5755042. DOI: 10.1182/blood-2017-06-741058. View

10.

Moore G, Bernett M, Rashid R, Pong E, Nguyen D, Jacinto J . A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods. 2018; 154:38-50. DOI: 10.1016/j.ymeth.2018.10.006. View

11.

Engelberts P, Hiemstra I, de Jong B, Schuurhuis D, Meesters J, Hernandez I . DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020; 52:102625. PMC: 6992935. DOI: 10.1016/j.ebiom.2019.102625. View

12.

Bonello F, Mina R, Boccadoro M, Gay F . Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers (Basel). 2019; 12(1). PMC: 7017131. DOI: 10.3390/cancers12010015. View

13.

Goldstein R, Goyos A, Li C, Deegen P, Bogner P, Sternjak A . AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020; 4(17):4180-4194. PMC: 7479952. DOI: 10.1182/bloodadvances.2020002565. View

14.

Subklewe M . BiTEs better than CAR T cells. Blood Adv. 2021; 5(2):607-612. PMC: 7839370. DOI: 10.1182/bloodadvances.2020001792. View

15.

Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y . Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020; 4(18):4538-4549. PMC: 7509877. DOI: 10.1182/bloodadvances.2020002393. View

16.

Mikkilineni L, Kochenderfer J . CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2020; 18(2):71-84. DOI: 10.1038/s41571-020-0427-6. View

17.

Lancman G, Richter J, Chari A . Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):264-271. PMC: 7727546. DOI: 10.1182/hematology.2020000110. View

18.

Freedman A, Jacobsen E . Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2019; 95(3):316-327. DOI: 10.1002/ajh.25696. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

20.

Shah N, Chari A, Scott E, Mezzi K, Usmani S . B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020; 34(4):985-1005. PMC: 7214244. DOI: 10.1038/s41375-020-0734-z. View